David Nayagam from E & P covers PYC. Has release a speculative buy note out today with a 24c valuation. He notes "developmental molecular therapies targeting monogenic conditions with clear genotypic-phenotypic associations enjoy tantalizingly high probabilities of success". Still adopts a conservative approach to the current valuation and ascribes zero value to the third and fourth pipeline assets (PM and PKD).
Ann: Investor Presentation ADOA Program, page-25
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.5¢ | 16.5¢ | $182.4K | 1.076M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 338966 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 244886 | 5 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| PYC (ASX) Chart |